Clinical Data – Talk Bio

AstraZeneca Expands AI Collaboration with SOPHiA GENETICS for Breast Cancer Research

3 weeks ago talkbio0Tagged AI Factories, AstraZeneca, Clinical Data, Genomics, Malignant neoplasm of breast, predictive models, real-world evidence, SOPHiA GENETICS

AstraZeneca; SOPHiA GENETICS; AI Factories; breast cancer; predictive models; real-world evidence; genomics; clinical data

FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy

1 month ago talkbio0Tagged Capricor Therapeutics, Cardiomyopathies, Cell Therapy, Clinical Data, Complete, deramiocel, HOPE-3 trial, Muscular Dystrophy, Duchenne, Phase 3, Rejection, Response process, United States Food and Drug Administration

FDA rejection; Capricor Therapeutics; deramiocel; Duchenne muscular dystrophy; DMD; cell therapy; cardiomyopathy; clinical data; Phase 3 HOPE-3 trial; Complete Response Letter

Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines

2 months ago talkbio0Tagged Clinical Data, COVID19 (disease), immune compromise, Invivyd, long-acting protection, Monoclonal Antibodies, Pemgarda, vaccine alternatives

Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data

Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate

2 months ago talkbio0Tagged Amylin Candidate, aspects of adverse effects, Clinical Data, early-stage trial, Eli, Eli Lilly, Eloralintide, Obesity, Weight Loss

Eli Lilly; eloralintide; amylin candidate; weight loss; early-stage trial; obesity drug; clinical data; side effects

GLP-1s May Lower Cancer Risk; Gyre Stock Drops After Hep B Data, Share Offering

3 months ago talkbio0Tagged agonists, Cancer Risk, Clinical Data, GLP-1 receptor, Gyre stock, Hepatitis B, Mortality Vital Statistics, Obesity-Related Cancers

GLP-1 receptor agonists; cancer risk; obesity-related cancers; Gyre stock; hepatitis B; clinical data; mortality

Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS

1 year ago talkbio0Tagged BMS, Cardiomyopathies, Cardiovascular Diseases, Clinical Data, Cytokinetics, Heart failure, mecarbil, Myocardium, myosin inhibitors, omecamtiv, Phase 3 Clinical Trials

Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.